Recent progress of nuclear medicine evaluation of curative effect of 223Ra dichloride treatment on castration- resistant prostate cancer and bone metastases
Radium-223 dichloride (223Ra) (Sofigo), a calcium-mimetic agent that specifically targets bone lesions, was approved in 2020 by China Food and Drug Administration (CFDA) to treat castration‑resistant prostate cancer and bone metastases (CRPC) with symptomatic bone metastases and no known visceral me...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Science Press
2021-12-01
|
| Series: | He jishu |
| Subjects: | |
| Online Access: | http://www.hjs.sinap.ac.cn/thesisDetails#10.11889/j.0253-3219.2021.hjs.44.120301&lang=zh |
| _version_ | 1811169657245138944 |
|---|---|
| author | LOU Jingjing LI Tongtong LIU Xingdang ZHANG Hong |
| author_facet | LOU Jingjing LI Tongtong LIU Xingdang ZHANG Hong |
| author_sort | LOU Jingjing |
| collection | DOAJ |
| description | Radium-223 dichloride (223Ra) (Sofigo), a calcium-mimetic agent that specifically targets bone lesions, was approved in 2020 by China Food and Drug Administration (CFDA) to treat castration‑resistant prostate cancer and bone metastases (CRPC) with symptomatic bone metastases and no known visceral metastatic diseases. It is the fisrt α particles targeted radiopharmaceutical therapeutic drugs in the world to be applied to CRPC with bone metastase (mCRPC) patients. In recent years, the application of nuclear medicine technology to evaluate the efficacy of 223Ra in the treatment of mCRPC patients abroad has been very common, but only few hospitals in China have entered the stage of clinical application. In order to provide clear recommendations for clinical applications of radionuclide imaging in evaluating the efficacy of 223Ra in the treatment of mCRPC, a survey of recent progress is carried out in this study, and public available clinical data of single photon emission computed tomography/computed tomography (SPECT/CT), and positron emission tomography/computed tomography (PET/CT) using radiolabeled chemical agents worldwide in the evaluation of 223Ra treatment for patients with CRPC and bone metastase,are presented and commented. |
| first_indexed | 2024-04-10T16:46:54Z |
| format | Article |
| id | doaj.art-c6835d4c83094a70898911d93b711d41 |
| institution | Directory Open Access Journal |
| issn | 0253-3219 |
| language | zho |
| last_indexed | 2024-04-10T16:46:54Z |
| publishDate | 2021-12-01 |
| publisher | Science Press |
| record_format | Article |
| series | He jishu |
| spelling | doaj.art-c6835d4c83094a70898911d93b711d412023-02-08T00:42:10ZzhoScience PressHe jishu0253-32192021-12-01441212030112030110.11889/j.0253-3219.2021.hjs.44.1203010253-3219（2021）12-0035-07Recent progress of nuclear medicine evaluation of curative effect of 223Ra dichloride treatment on castration- resistant prostate cancer and bone metastasesLOU Jingjing0LI Tongtong1LIU Xingdang2ZHANG Hong3Department of Nuclear Medicine, the Second Hospital of Zhejiang University School of Medicine, Hangzhou 310009, ChinaDepartment of Nuclear Medicine, Huashan Hospital, Fudan University, Shanghai 200040, ChinaDepartment of Nuclear Medicine, Pudong Hospital, Fudan University, Shanghai 201399, ChinaDepartment of Nuclear Medicine, the Second Hospital of Zhejiang University School of Medicine, Hangzhou 310009, ChinaRadium-223 dichloride (223Ra) (Sofigo), a calcium-mimetic agent that specifically targets bone lesions, was approved in 2020 by China Food and Drug Administration (CFDA) to treat castration‑resistant prostate cancer and bone metastases (CRPC) with symptomatic bone metastases and no known visceral metastatic diseases. It is the fisrt α particles targeted radiopharmaceutical therapeutic drugs in the world to be applied to CRPC with bone metastase (mCRPC) patients. In recent years, the application of nuclear medicine technology to evaluate the efficacy of 223Ra in the treatment of mCRPC patients abroad has been very common, but only few hospitals in China have entered the stage of clinical application. In order to provide clear recommendations for clinical applications of radionuclide imaging in evaluating the efficacy of 223Ra in the treatment of mCRPC, a survey of recent progress is carried out in this study, and public available clinical data of single photon emission computed tomography/computed tomography (SPECT/CT), and positron emission tomography/computed tomography (PET/CT) using radiolabeled chemical agents worldwide in the evaluation of 223Ra treatment for patients with CRPC and bone metastase,are presented and commented.http://www.hjs.sinap.ac.cn/thesisDetails#10.11889/j.0253-3219.2021.hjs.44.120301&lang=zh223ramcrpcspect/ctpet/ct |
| spellingShingle | LOU Jingjing LI Tongtong LIU Xingdang ZHANG Hong Recent progress of nuclear medicine evaluation of curative effect of 223Ra dichloride treatment on castration- resistant prostate cancer and bone metastases He jishu 223ra mcrpc spect/ct pet/ct |
| title | Recent progress of nuclear medicine evaluation of curative effect of 223Ra dichloride treatment on castration- resistant prostate cancer and bone metastases |
| title_full | Recent progress of nuclear medicine evaluation of curative effect of 223Ra dichloride treatment on castration- resistant prostate cancer and bone metastases |
| title_fullStr | Recent progress of nuclear medicine evaluation of curative effect of 223Ra dichloride treatment on castration- resistant prostate cancer and bone metastases |
| title_full_unstemmed | Recent progress of nuclear medicine evaluation of curative effect of 223Ra dichloride treatment on castration- resistant prostate cancer and bone metastases |
| title_short | Recent progress of nuclear medicine evaluation of curative effect of 223Ra dichloride treatment on castration- resistant prostate cancer and bone metastases |
| title_sort | recent progress of nuclear medicine evaluation of curative effect of 223ra dichloride treatment on castration resistant prostate cancer and bone metastases |
| topic | 223ra mcrpc spect/ct pet/ct |
| url | http://www.hjs.sinap.ac.cn/thesisDetails#10.11889/j.0253-3219.2021.hjs.44.120301&lang=zh |
| work_keys_str_mv | AT loujingjing recentprogressofnuclearmedicineevaluationofcurativeeffectof223radichloridetreatmentoncastrationresistantprostatecancerandbonemetastases AT litongtong recentprogressofnuclearmedicineevaluationofcurativeeffectof223radichloridetreatmentoncastrationresistantprostatecancerandbonemetastases AT liuxingdang recentprogressofnuclearmedicineevaluationofcurativeeffectof223radichloridetreatmentoncastrationresistantprostatecancerandbonemetastases AT zhanghong recentprogressofnuclearmedicineevaluationofcurativeeffectof223radichloridetreatmentoncastrationresistantprostatecancerandbonemetastases |